- Home
- CNEY vs PSTV Comparison
CNEY vs PSTV Comparison
Compare CNEY & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- PSTV
- Stock Information
- Founded
- CNEY 2018
- PSTV 1996
- Country
- CNEY China
- PSTV United States
- Employees
- CNEY N/A
- PSTV N/A
- Industry
- CNEY Major Chemicals
- PSTV Medical/Dental Instruments
- Sector
- CNEY Industrials
- PSTV Health Care
- Exchange
- CNEY Nasdaq
- PSTV Nasdaq
- Market Cap
- CNEY 2.1M
- PSTV 2.1M
- IPO Year
- CNEY 2021
- PSTV N/A
- Fundamental
- Price
- CNEY $0.13
- PSTV $0.79
- Analyst Decision
- CNEY
- PSTV Strong Buy
- Analyst Count
- CNEY 0
- PSTV 3
- Target Price
- CNEY N/A
- PSTV $11.50
- AVG Volume (30 Days)
- CNEY 9.0M
- PSTV 3.8M
- Earning Date
- CNEY 01-01-0001
- PSTV 05-14-2025
- Dividend Yield
- CNEY N/A
- PSTV N/A
- EPS Growth
- CNEY N/A
- PSTV N/A
- EPS
- CNEY N/A
- PSTV N/A
- Revenue
- CNEY $50,957,974.00
- PSTV $5,824,000.00
- Revenue This Year
- CNEY N/A
- PSTV $13.26
- Revenue Next Year
- CNEY N/A
- PSTV $24.59
- P/E Ratio
- CNEY N/A
- PSTV N/A
- Revenue Growth
- CNEY N/A
- PSTV 18.54
- 52 Week Low
- CNEY $0.11
- PSTV $0.24
- 52 Week High
- CNEY $1.60
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- CNEY 44.70
- PSTV 47.37
- Support Level
- CNEY $0.11
- PSTV $0.61
- Resistance Level
- CNEY $0.20
- PSTV $1.22
- Average True Range (ATR)
- CNEY 0.02
- PSTV 0.13
- MACD
- CNEY 0.00
- PSTV 0.02
- Stochastic Oscillator
- CNEY 23.09
- PSTV 29.16
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).